Source: US Department of Health and Human Services
CMS Expands Access to Lifesaving Gene Therapies Through Innovative State Agreements
Participating states to test outcomes-based payments for sickle cell disease treatments, improving care while lowering long-term costs
The Centers for Medicare & Medicaid Services (CMS) announced today that 33 states, plus the District of Columbia and Puerto Rico, will participate in the Cell and Gene Therapy (CGT) Access Model, a bold new approach to delivering cutting-edge treatments for people on Medicaid living with sickle cell disease. Participating states represent approximately 84% of Medicaid beneficiaries with the condition, significantly expanding access to transformative care.